Press Releases Year None202120202019201820172016 Sep 15, 2021 Imara to Participate in Upcoming Investor Conferences Sep 03, 2021 Imara to Present at Upcoming Investor Conferences Aug 06, 2021 Imara Reports Second Quarter 2021 Financial Results and Business Highlights Aug 05, 2021 Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease Jul 30, 2021 Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights Jul 13, 2021 Imara Announces Pricing of Public Offering Jul 13, 2021 Imara Announces Launch of Proposed Public Offering Jun 30, 2021 Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors Jun 17, 2021 Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders Jun 11, 2021 Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 20
Press Releases Year None202120202019201820172016 Sep 15, 2021 Imara to Participate in Upcoming Investor Conferences Sep 03, 2021 Imara to Present at Upcoming Investor Conferences Aug 06, 2021 Imara Reports Second Quarter 2021 Financial Results and Business Highlights Aug 05, 2021 Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease Jul 30, 2021 Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights Jul 13, 2021 Imara Announces Pricing of Public Offering Jul 13, 2021 Imara Announces Launch of Proposed Public Offering Jun 30, 2021 Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors Jun 17, 2021 Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders Jun 11, 2021 Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 20
Aug 05, 2021 Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
Jul 30, 2021 Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
Jun 17, 2021 Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
Jun 11, 2021 Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
